The strategic agreement between Gsk (https://www.gsk.com/) and Orchard Therapeutics (http://orchard-tx.com/) includes approved and investigational rare disease gene therapies, that will be transferred to Orchard, while Gsk will become an investor in the company, receiving a 19.9% equity stake along with a seat on the board. UK-based Orchard Therapeutics is mainly focused on clinical and preclinical gene therapies for primary immune deficiencies and inherited metabolic disorders. The acquired portfolio includes Strimvelis, the first autologous ex vivo gene therapy for children with adenosine deaminase severe combined immunodeficiency (ADA-SCID), two late-stage clinical programmes for metachromatic leukodystrophy (MLD) and Wiskott Aldrich syndrome (WAS), and one clinical programme for beta thalassaemia.